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Abstract: Apart from its metabolic or physiological functions, melatonin has a potent cytoprotective activity in the physiological and
pathological conditions. It is synthetized by the pineal gland and released into the blood circulation but particularly cerebrospinal fluid
in a circadian manner. It can also easily diffuse through cellular membranes due its small size and lipophilic structure. Its cytoprotective
activity has been linked to its potent free radical scavenger activity with the desirable characteristics of a clinically- reliable antioxidant.
Melatonin detoxifies oxygen and nitrogen-based free radicals and oxidizing agents, including the highly toxic hydroxyl-and peroxynitrite
radicals, initiating cellular damage. However, the cytoprotective activity of melatonin is complex and cannot be solely limited to its free
radical scavenger activity. It regulates cellular signaling pathways through receptor– dependent and independent mechanisms. Most of
these downstream molecules, such as PI3K/AKT pathway components, also contribute to the cytoprotective effects of melatonin. In this
term, melatonin is a promising molecule for the treatment of neurodegenerative disorders, such as ischemic stroke, which melatonin
reduces ischemic brain injury in animal models of ischemic stroke. It regulates also circadian rhythm proteins after ischemic stroke,
playing roles in cellular survival. In this context, present article summarizes the possible role of melatonin in the pathophysiological
events after ischemic stroke.
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1. Introduction
Stroke is one of the leading causes of death and long-term
disability worldwide [1] with increasing incidence rates
in low and middle-income countries [2]. Disability due
to a stroke incidence has significant emotional, social and
economic burden on the patients and their society. It was
suggested that deaths due to stroke cases will reach to 12
million and number of patients surviving from a stroke
incidence will reach to about 70 million by the year 2030
[3].
Stroke cases are categorized into two groups:
hemorrhagic and thrombotic (or ischemic) stroke. In
hemorrhagic stroke, intracerebral or subarachnoid
hemorrhage occurs in the brain due to the rupture of
a cerebral blood vessel, but this type of stroke is less
common (about 15% of all stroke cases in USA and
Europe) worldwide [4,5]. On the other hand, ischemic
stroke contributes to the majority of stroke cases and
occurs when a cerebral artery is occluded by thrombus or

thromboembolism, meaning that a blood clot may occur
and cause a block in a small cerebral artery or a blot clot
formed in a large vessel lodges in a small vessel in the brain.
Due to the occlusion of the cerebral artery, blood supply to
a certain brain region is restricted. Therefore, this event is
called ischemia or ischemic stroke.
Despite being a global problem with major social and
economic burden on the society, treatment strategies are
limited, and prevention measures are not enough [1].
Currently, patients survived from an ischemic stroke are
treated with tissue plasminogen activator (tPA) that helps
to relieve the obstruction in the blood vessels [6]. However,
tPA has a very short therapeutic window which makes it
impossible to use in the majority of the patients because
of unfavorable actions of thrombolytics. Therefore,
researchers have been in the search for a treatment option
that can be used in patients who were diagnosed after the
end of the therapeutic window of tPA or add-on treatment
with thrombolytics. In this sense, it was shown that
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melatonin also reverses unfavorable actions of tPA [7] and,
we will focus on the novel findings for the use of melatonin
in ischemic brain injury in the present article.
The pathophysiologic mechanisms underlying
ischemic stroke or ischemia/reperfusion injury in humans
include loss of the prooxidant/antioxidant balance,
excitotoxicity and related increase in intracellular Ca++
levels, dysfunction in mitochondrial processes, increased
neuroinflammation and eventually apoptotic neuronal cell
death [8].
2. Justification of use of melatonin in stroke treatment
The studies reporting the antioxidant effects of melatonin
justified its use for treatment of ischemic injury in animal
models [9]. Thereafter, further research provided evidence
that melatonin is able to alleviate several of the detrimental
effects of stroke-related pathophysiologic processes [10,11].
In addition, melatonin was shown to protect the integrity
of blood-brain barrier [12] and vascular function in the
brain [13], bind and neutralize heavy metals [14] promote
neuronal survival [15,16], and functional recovery [17]
with minimal, if any, side effects even in high doses [18].
Moreover, melatonin exerts neurological protection by
reducing the cerebral inflammatory response, cerebral
edema and brain-blood barrier permeability after ischemic
stroke [19].
Although melatonin can be synthesized in a number of
tissues, it is believed that the main production center may be
the pineal gland due to the fact that melatonin’s protective
effects are severely diminished by pinealectomy as reported
in experimental model of stroke [20]. Melatonin synthesis
in the pineal gland occurs in a circadian manner, in which
the melatonin levels peak in the night-time, whereas in the
day-time melatonin production is inhibited [21]. Secreted
melatonin is believed to modulate the circadian clock
mechanisms through the ubiquitin-proteasome signaling
pathway. Several gene transcripts [22] and proteins [23]
have been identified to be expressed in a circadian fashion.
Of these genes, the six core clock genes are known as Per1
and Per2, Cry1 and Cry2, Clock and Bmal1 [24,25]. We
have reported that melatonin regulates Bmal1 expression
under normal conditions in vitro after hypoxia and in vivo
after ischemic stroke [26]. Interestingly, in parallel with the
highest blood concentrations of melatonin, the ischemic
stroke incidence is lowest at the midnight hours in human
[27]. In this term, we have indicated that tolerance to
ischemic injury changes according to the time of day in
which the injury occurs and the underlying mechanism of
this tolerance includes circadian clock genes, specifically
Bmal1, which is also regulated by the phosphorylation
of AKT signaling pathway [24]. Consistently, Bmal1
expression is enhanced following melatonin treatment
following ischemic brain injury in mice and this increase
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is blocked when the survival kinase AKT inhibitors are
present [26]. In addition to the transcriptional control
of Bmal1 gene, melatonin may also regulate clock genes
by stabilizing the protein through the inhibition of the
ubiquitin-proteasome system [28]. It has been speculated
that melatonin can act as a proteasome inhibitor and we
showed that melatonin inhibits the proteasome machinery
by downregulating Nedd4-1 E3 ligase expression [29].
Collectively, these data suggest that melatonin may
still have unelucidated roles in the body that promotes
endogenous recovery systems.
3. Melatonin’s antioxidant effect
The experimental models in rodents focusing on the
antioxidant effect of melatonin in stroke pathophysiology
mainly involved in the ischemia/reperfusion. In this
model, generally transiently middle cerebral artery
occlusion (MCAo) is performed and melatonin is usually
administered either at the onset of ischemia or reperfusion
[8]. In the ischemia/reperfusion injury, a blood vessel is
obstructed and blood supply to a certain brain region is
restricted, causing immediate apoptotic and necrotic cell
death in the ischemic core. The surrounding tissue, called
the penumbra, has relatively higher levels of blood supply
compared to the ischemic core, however, apoptotic cell
death through the complex interplay of several mechanisms
can be observed in the penumbra even several days after
ischemic injury [8]. In order to resupply the ischemic brain
tissue with oxygen, hyperbaric (HBO) and normobaric
oxygen (NBO) treatments gained considerable interest due
to the possibility of oxygen to diffuse through the bloodbrain barrier to reach the injured brain tissue. However,
conflicting literature exists for HBO treatment in transient
or permanent MCAO models possibly because of increased
free radical production upon effect of oxygen [30]. Even
detrimental effects of HBO treatment were reported
[31], but it should be kept in mind that the underlying
reason for conflicting results may be partly because of
the different timing of HBO treatment. Conversely, NBO
therapy is an inexpensive and easy-to-access strategy that
can be administered by simple facemasks. The favorable
effects of NBO on the infarct volume and cell death were
demonstrated in different models of brain injury [32–35].
However, the NBO treatment in these studies is usually
started during the ischemia period or immediately at the
onset of reperfusion. Although NBO can be beneficial in
these models, this therapy can be only translated to patients
who were admitted to hospitals with stroke symptoms that
last for less than 12 h. In the light of these results, our group
investigated the use of NBO treatment during reperfusion
[12]. We also evaluated the combination of melatonin
with NBO treatment. Our results indicated that melatonin
potentiated the protective effect of NBO therapy in terms
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of infarct volume, brain swelling, neurological deficit score
and DNA fragmentation [12].
Even though the most important step in rescuing
the cells’ from apoptotic death in the penumbra is to
remove the obstruction and resupply the blood flow
(i.e. reperfusion), this results in oxidative damage due
to the excess production of free radicals. The cells of the
central nervous system (CNS) are already exposed to high
amounts of free radicals in the physiological state. The
adult human brain uses about 20% of the total oxygen
intake even though it weighs only about 2% of the total
body weight [36]. Not only brain produces the highest
number of free radicals compared to any other organ in
the body, but also it has high levels of polyunsaturated fatty
acids which make it more prone to oxidative stress. Under
normal conditions, the production of free radicals and
antioxidant enzymes are kept in a delicate balance. If an
imbalance occurs in favor of oxidants as a result of brain
injury, the ability of the CNS cells to neutralize oxidants
using endogenous antioxidant systems is overwhelmed
and eventually inflammation and apoptotic cell death are
observed.
It is well-known that the free radicals including reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
including superoxide anions (O2•−), hydrogen peroxide
(H2O2), hydroxyl radicals (HO•) nitric oxide (•NO) and
peroxynitrite (ONOO−) are mainly produced during the
reperfusion phase of an ischemic stroke. The sources of
these free radicals are diverse. For instance, nitric oxide
is a signaling molecule that is involved in vasodilatation,
neurotransmission and blood pressure maintenance and
is synthesized by NO synthase (NOS) enzymes mainly in
a calcium-dependent manner [37]. Three types of NOS
enzymes were characterized as neuronal NOS (nNOS),
inducible NOS (iNOS) and endothelial NOS (eNOS) in the
central nervous system [38]. During ischemic brain injury,
excess nitric oxide is generated, which in turn results in
lipid peroxidation, energy depletion, and formation of
highly neurotoxic oxidizing agent ONOO− [39]. Although
the nitric oxide synthesized by the eNOS at the early phases
of ischemic stroke is believed to provide protective effects,
NO synthesis by iNOS and nNOS exacerbates the injury
by activating the inflammatory mechanisms [40].
It has become clear that excessive free radical
generation is a critical pathophysiological step in ischemic
injury and regulates several other steps. This prompted
researchers to investigate the possible use of chemical
or biological molecules to reduce the generation or
accumulation of free radicals. We and others have tested
several antioxidant molecules, such as glutathione [41],
vitamin E [42], vitamin C [43] or melatonin [20]. To the
best of our knowledge, melatonin is the only antioxidant
whose metabolites also have antioxidant capacities. In

fact, the direct and indirect capacity of melatonin and
its metabolites (c3OHM, AFMK and AMK) to scavenge
free radicals is called the “antioxidant cascade” [44]. As
the members of the antioxidant cascade of melatonin
are all free radical scavengers, the detoxification capacity
of melatonin was predicted to be up to 10 times more
than any other antioxidant molecule [45]. Therefore,
antioxidant capacity of melatonin has been studied in
many ischemia/reperfusion injury models, including
brain, kidney or heart. In fact, melatonin can interact with
and detoxify the free radicals by donating an electron or
a hydrogen atom in the injury models. In addition to its
free radical scavenger activity, melatonin was also shown
to upregulate antioxidant enzymes, such as superoxide
dismutase (SOD), catalase or glutathione reductase (GR)
[46]. Our group evaluated the effect of melatonin on the
production of nitric oxide and our results demonstrate
that melatonin treatment significantly downregulates
nNOS and iNOS after ischemic brain injury [7,47].
4. Melatonin in mitochondria
Considering the higher melatonin concentrations
compared to blood levels were measured in rat liver
mitochondria [48], it is not surprising to assume that high
melatonin levels are required to protect the mitochondrial
DNA from the continuous production of reactive oxygen
species by the oxidative phosphorylation [49]. Because of
its lipophilic structure, melatonin can easily pass through
the biological membranes and accumulate in organelles,
such as mitochondria and nuclei. Since the discovery
of melatonin in bacteria and chloroplasts,it has been
speculated that melatonin synthesis can also occur in the
mitochondria [50]. Furthermore, enzymes (although not
all) required for the synthesis of melatonin were detected
in oocyte mitochondria [51]. These results strongly suggest
that melatonin synthesized in the mitochondria is used
as direct free radical scavenger and indirect antioxidant
enzyme regulator in this organelle. Moreover, in a recent
study, mitochondrial melatonin was shown to be secreted
into the cytosol where it can bind to the receptors on the
surface of the mitochondria [52]. It is proposed that this
feature gives another advantage to melatonin in its role in
mitochondrial homeostasis. This involves the restoration
of the activity and expression of complexes I and IV which
are decreased during ischemic injury. This in turn, reduces
the electron leakage and prevents further damage to the
organelle.
In addition, increased free Ca++ levels following
ischemic brain injury are also responsible for mitochondrial
dysfunction and formation of further free radicals. If these
toxic effects are not neutralized, ATP production would
be severely affected. Intriguingly, Xu et al. implicated
that melatonin can control free Ca++ movement in the
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cytoplasm and protects the homeostasis of mitochondria
[53].
5. Melatonin’s antiapoptotic effect
Loss of blood supply during ischemic brain injury
depletes the cellular energy and results in the release of
glutamate neurotransmitter into the extracellular space
[8]. As a result, the transmembrane glutamate receptors
(such as NMDA, AMPA or kainic acid receptors) and
several channel and transporter proteins (such as TRPM2,
TRPM7, NCX, ASICs, CaV1.2) are overactivated.
Activation of these receptors is followed by an excessive
Ca++ influx, either due to the release from mitochondria
and endoplasmic reticulum or due to activation of plasma
membrane proteins and lead to apoptotic cell death [54].
Of these receptors, overactivation of postsynaptic NMDA
receptors by glutamate results in increased Ca++ load
in the cytosol and mitochondria [55]. In this term, we
used a combination treatment with an NMDA receptor
inhibitor, memantine, and melatonin in a MCAo model
and our results indicate that administration of melatonin/
memantine combination significantly reduces the infarct
volume, while improving the vascular leakage [56].
Furthermore, electrophysiological studies revealed that
melatonin depresses NMDA receptor activity in the brain,
possibly due to reduced nNOS activity [56,57].
In an attempt to rescue from Ca++ overload, the cells
in the injured brain tissue try to reduce the high cytosolic
Ca++ levels by storing Ca++ ions into mitochondria
or endoplasmic reticulum. However, when Ca++
levels are increased in the mitochondrial matrix, free
radical production is enhanced. Increased free radical
accumulation disrupts mitochondrial membrane, results
in permeabilization and depolarization followed by the
release ofproapoptotic molecules, such as cytochrome
c and apoptosis inducing factor (AIF) into the cytosol
[58,59]. Andrabi et al. suggested that melatonin inhibits
the cytochrome c release and decreases DNA damage
in transient MCAO in rats [60]. Our results proved that
melatonin improves neuronal survival by caspase-3
inhibition [16]. In addition, we showed that melatonin
inhibits antiapoptotic Bcl-xL, while promoting the
expression of proapoptotic Bax [12]. Downregulation of
survival kinases in the injured brain tissue also contributes
to apoptotic cell death. It is well-known that ischemia/
reperfusion inhibits PI3K/AKT pathway. Our planar
immunoassay analyses revealed that melatonin treatment
results in the increased AKT phosphorylation especially at
the Thr308 site of the activation loop via PDK1 and PTEN
as well as decreased GSK-3α/β, and p53 phosphorylations
[19], suggesting that neuroprotective activity of melatonin
directly involves the activation of survival signaling
pathways. Additionally, we have observed that melatonin
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treatment phosphorylates AMPKα, which is particularly
activated by the reduced intracellular energy. AMPKα
drives the cell to a catabolic state which this molecule
mobilizes alternative energy sources, such as fatty acid
oxidation, in order to supply ATP in the condition of
ischemic stroke, suggesting also that melatonin may
activate alternative collateral survival pathways [19].
6. Melatonin’s antiinflammatory effect
It has been shown that one of the early mechanisms of
ischemic injury is the release of inflammatory cytokines,
such as IL1β, IL6 and TNFα [61]. Following an ischemic
attack in the brain, the free radicals are generated in
high amounts. This excessive free radical production
especially during the reperfusion phase also contributes
to the disruption of the integrity of the blood-brain
barrier and stimulates the infiltration of lymphocytes,
neutrophils, monocytes, T cells, and macrophages to the
injury site [62]. Simultaneously, resident microglial cells
are activated, change their morphology (deramification)
and start to release proinflammatory cytokines. Microglial
activation following ischemia also results in increased
proliferation and accumulation in the penumbra region.
Microglial activation seems to have a dual role in the
pathophysiology of stroke. During the course of ischemia/
reperfusion, microglial cells are believed to switch from
an antiinflammatory state to proinflammatory phenotype
[63]. Melatonin treatment was shown to inhibit the
proinflammatory shift of microglial cells through the
regulation of SIRT1 and STAT3 [64,65]. Moreover, TLR4
activates NF-κB after stroke, resulting in the secretion of
inflammatory molecules (IL1β, IL6 and TNFα). Melatonin
decreases the secretion of inflammatory mediators
by downregulating NF-κB, while promoting Nrf2
upregulation [66].
7. Roles of melatonin receptors in stroke treatment
Studies indicated increased melatonin levels can be
observed as early as in the first 10 minutes of intraperitoneal
or subcutaneous application, indicating that melatonin
can easily pass through the blood-brain barrier [67].
Melatonin is also able to diffuse through cellular and
organelle membranes due its small size and lipophilic
structure [68]. On the other hand, melatonin has two G
protein-coupled transmembrane receptors; MT1 and MT2
(earlier names Mel1a and Mel1b) which are ubiquitously
found in almost all cells in the body [69]. It has been
proposed that melatonin exerts its neuroprotective effects
on the brain by both receptor-independent or receptor
dependent mechanisms [70]. Models of acute and chronic
ischemia have been used to investigate the role of MT1/
MT2 receptors in ischemic brain injury by using melatonin
receptor agonists, such as ramelteon [71,72], agomelatine
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[73,74] or Neu-P11 [75]. Activation of MT1/MT2 receptors
by the aforementioned agonists reduced infarct volume
through the regulation of different signaling molecules.
In 2010, it was reported that melatonin administration
promotes the expression of MT2 in the ischemic tissue and
due to this increase, the authors suggested that MT2 may
partially mediate the effects of melatonin [76]. Chern et al.
reported that chemical antagonists of MT2 could reverse
the protective effect of melatonin in a transient brain
ischemia model [77]. However, in a previous report where
we used a transient focal cerebral ischemia model in MT1/
MT2 knockout mice, we showed that melatonin treatment
significantly decreased brain damage, suggesting that
it does not require the interplay of these receptors for
exerting neuroprotective effects [47]. In the light of these
results, we hypothesized that although the activation of
MT1/MT2 receptors protects the brain from ischemic
injury, melatonin does not require MT1/MT2 receptor
activation to exert neuroprotection. However, it should be
noted that melatonin has another membrane-associated
receptor, MT3 (also known as quinone reductase 2, QR2),
found in thecells of liver, kidney, heart, lung, intestine,
adipose tissues or in brain cells [78,79] and whether it
is involved in melatonin’s antioxidant, antiapoptotic or
antiinflammatory activity should be further investigated.
Interestingly, MT3 knockout mice were less susceptible
to menadione toxicity [80], suggesting that the inhibition
of this receptor may have protective effects. Moreover,
knockdown of MT3 by RNA interference in vitro resulted
in enhanced expression of antioxidant enzymes [81], while
overexpression of MT3 resulted in excessive production of
reactive oxygen species [82]. It was shown that melatonin
is able to inhibit this receptor at nanomolar levels in which
antioxidant effects were documented [83]. Therefore, it is
tempting to speculate that MT3 inhibition by melatonin
is involved in melatonin’s protective effects on the
pathophysiological outcomes of brain injury not only by
increasing the expression of antioxidant enzymes, but also
by providing resistance to oxidative stress.
Moreover, the nuclear receptors RZR/ROR from
the retinoic acid receptor superfamily were proposed
as nuclear binding sites for melatonin [84]. RZR/ROR
expression was demonstrated in the brain, and in the
pineal gland [69]. ROR receptors were shown to induce
the expression of several clock genes, including Clock,
Cry or Bmal1 [85–87] by binding to retinoic acidrelated orphan receptor response elements (ROREs) in
the promoter region. In parallel with these data, cyclic
expression of ROR mRNAs were noted in different tissues,
suggesting a circadian function possibly under the control
of melatonin. However, whether these receptors play a
part in the protective mechanisms induced by melatonin
should be further investigated.

8. New roles for melatonin: regulation of circular RNA
in ischemic injury
Recently, noncoding RNAs including microRNAs,
long noncoding RNAs, and circular RNAs have gained
considerable attention as regulatory molecules. Recent
studies indicated that circular RNAs (circRNAs) are
found abundantly in the brain and are involved in the
embryonic development [88]. CircRNAs are enriched
in specific brain regions such as cerebellum, cortex,
striatum, olfactory bulbs, and hippocampus. Since
they are circular, these types of noncoding RNAs are
more resistant to digestion. CircRNAs can be made
from introns, coding or noncoding exons, or from both
exons and introns by a process called “back-splicing”
[89]. Zhang et al. suggested that because the circRNAs
are formed by the circularization of skipped exons,
formation of circRNA can cause the downregulation of
its parental gene by using up the pre-mRNA molecules
[90]. In addition to their regulatory roles in the brain,
circRNAs are also associated with neurological disorders,
including, but not limited to, ischemia/reperfusion injury,
traumatic brain injury, and Alzheimer’s disorder [91]. In
a study performed in acute ischemic stroke patients to
profile the changes in circRNA, 3 circRNAs have been
proposed as diagnostic and predictive biomarkers for
stroke [92]. Significantly altered circRNAs in a transient
MCAO model in C57BL/6J mice were characterized, and
bioinformatics data suggested that all these circRNAs
possess binding sites for microRNAs [93]. However, the
exact pathophysiological mechanisms that they have a
role in are not fully elucidated. It has been predicted that
melatonin may be involved in the regulation of circRNAs
as the circRNA prolife in the pineal gland has been altered
in a mouse model of Alzheimer’s disease [94]. In fact, a
recent study reported that melatonin exerts protective
effects through the regulation of CircRIC3/miR-2045p/DPP4 signaling in calcific aortic valve disease [95].
Therefore, we hypothesized that melatonin also regulates
circRNAs in ischemia/reperfusion injury, however, these
circRNAs should be further investigated in future studies.
9. Prophylactic use in high risk individuals
Moreover, we reported that lower endogenous melatonin
concentrations were associated with increased injury after
transient ischemic stroke in pinealectomized rats and when
those deprived animals were given exogenous melatonin,
injury size could be reduced [20]. It has been shown that
melatonin levels are reduced in elderly compared to young
adults; therefore, aged population is more prone to serious
ischemic injury [96]. In addition, accumulation of other
risk factors, such as cardiovascular disorders, diabetes,
obesity or hypertension with ageing increases the risk of
ischemic injury incidence [97,98]. In animal models, we
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demonstrated that prophylactic uses, and delayed uses of
melatonin successfully protects the brain from the ischemic
injury [13,17]. In conclusion, prophylactic doses could be
considered in the elder population in order to compensate
for the reduced melatonin levels due to the calcification
of pineal gland and to promote the endogenous repair

mechanisms against stroke or other neurodegenerative
diseases.
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